• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

FDA Heightens Alert for Hepatitis B Virus With Rituximab


The FDA today advised physicians prescribing rituximab to screen and monitor all patients taking the drug for evidence of hepatitis B infection.

The US Food and Drug Administration today issued a new black-box warning for the immunosuppressant rituximab (Rituxan), boosting the level of vigilance for the risk of liver damage and death due to reactivation of prior hepatitis B infection among patients taking the drug. Rituximab is approved for rheumatologic conditions such as rheumatoid arthritis and vasculitis as well as for forms of lymphoma.

The Agency has also revised its guidance to doctors issuing new prescriptions for rituximab, recommending that they:

•    Screen all patients by hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before prescribing rituximab.
•    When screening identifies evidence of prior HBV infection, consult with hepatitis experts about monitoring and use of HBV antiviral therapy.
•    Monitor patients with evidence of prior HBV infection for clinical and laboratory signs of hepatitis B or HBV reactivation during rituximab treatment and for several months after it is withdrawn. Reactivations have occurred after completion of therapy, the FDA reports.
•     Immediately discontinue the drug if reactivation of HBV develops. The advisory says there is insufficient data to make any recommendation about resuming the drug for patients with hepatitis due to HBV reactivation after that condition is resolved.

The FDA warning also applies to the anti-cancer agent ofatumumab (Arzerra).

Both drugs are monoclonal antibodies that target the B-lymphocyte antigen CD20. Although a warning about the risk of HBV reactivation already existed on product packing, the FDA decided to strengthen the warning because cases of reactivation continued to arise.

Related Videos
Infectious disease specialist talks about COVID-19 vaccine development
COVID 19 impact on healthcare provider mental health
Physician mental health expert discusses impact of COVID-19 on health care workers
Related Content
© 2024 MJH Life Sciences

All rights reserved.